徐亚伟,张书宁

• 1:中国医师协会心血管内科医师分会
• 2:上海市第十人民医院
• 3:复旦大学附属中山医院

摘要(Abstract)：

<正>双联抗血小板治疗(dual-antiplatelet therapy,DAPT)一直以来是冠心病尤其是急性冠状动脉综合征(acute coronary syndrome,ACS)患者的抗栓治疗基础,但目前我国基层临床实践对指南相关推荐的依从性仍欠佳。抗血小板单片复方制剂(singlepill combination,SPC)的开发简化了治疗方案,便于患者管理,有望提高医师和患者对指南和处方的依从性,改善临床预后。为提高基层医师对规范抗血小板治疗的重视,更好地指导抗血小板SPC的合理使用,由中国医师协会心血管内科医师分会发起并制定了《氯吡格雷/阿司匹林单片复方制剂抗血小板治疗中国专家共识》。

关键词(KeyWords)： 氯吡格雷;阿司匹林;单片复方制剂;抗血小板治疗;专家共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 徐亚伟,张书宁

参考文献(References)：

• [1]中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要.中国循环杂志，2020, 35(9):833-854.
• [2] Moran A, Zhao D, Gu D, et al. The future impact of population growth and aging on coronary heart disease in China:projections from the Coronary Heart Disease Policy Model-China. BMC Public Health, 2008, 8:394.
• [3]中国胸痛中心联盟，中国心血管健康联盟，苏州工业园区心血管健康研究院等.《中国胸痛中心质控报告（2020）》概要.中国介入心脏病学杂志，2021,29(6):313-317.
• [4] O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol, 2013, 61(4):e78-e140.
• [5] Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of Patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol, 2014, 64(24):e139-e228.
• [6] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol, 2016, 68(10):1082-1115.
• [7] Ro ffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task f orce f or the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J, 2016, 37(3):267-315.
• [8] Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J, 2018, 39(2):119-177.
• [9]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南（2016）.中华心血管病杂志，2017, 45(5):359-376.
• [10]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南（2019）.中华心血管病杂志，2019, 47(10):766-783.
• [11] Zou Y, Yang S, Wang S, et al. Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction:2-year fi ndings from EPICOR Asia. Clin Cardiol, 2020, 43(4):346-354.
• [12] Xu JJ, Zhan G, Yin Z, et al. Dual antiplatelet therapy after coronary drug-eluting stent implantation in China:A large single center study. Catheter Cardiovasc Interv, 2018, 91(S1):566-572.
• [13] Bi Y, Gao R, Patel A, et al. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization:Results from the Clinical Pathways for Acute Coronary Syndromes in China(CPACS)study.Am Heart J, 2009, 157(3):509-516.e1.
• [14] Ma S, Jiang Z, Qiu M, et al. Dual antiplatelet therapy duration in medically managed acute coronary syndrome patients:Sub-analysis of the OPT-CAD Study. Adv Ther, 2020, 37(7):3150-3161.
• [15] Wu Y, Li S, Patel A, et al. Eff ect of a quality of care improvement initiative in patients with acute coronary syndrome in resourceconstrained hospitals in China:A randomized clinical trial. JAMA Cardiol, 2019, 4(5):418-427.
• [16] Sun Y, Li C, Zhang L, et al. Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients. Front Med, 2017, 11(1):53-61.
• [17] García-Donaire JA, Ruilope LM. Multiple action fi xed combination.Present or future? Fundam Clin Pharmacol, 2010, 24(1):37-42.
• [18]党爱民，叶蕴青.固定复方制剂：高血压患者理想的起始降压选择.中华高血压杂志，2010, 18(9):813-814.
• [19]科技部.“重大新药创制”科技重大专项“十二五”计划2012年新增课题申报指南. 2011.
• [20] Kim HK, Tantry US, Smith SC, et al. The East Asian Paradox:An updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease.Thromb Haemost,2021,121(4):422-432.
• [21] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J,2020,41(3):407-477.
• [22] Oh PC, Ahn T, Kim DW, et al. Comparative eff ect on platelet function of a fi xed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease:A phaseⅣ，multicenter, prospective, 4-week non-inferiority trial. Int J Cardiol, 2016, 202:331-335.
• [23] Wang L, Di Y, Guo T, et al. Implementation of a reference-scaled average bioequivalence approach for highly variable acetylsalicylic acid in fi xed-dose combination with clopidogrel versus enteric aspirin in Chinese subjects under fasting conditions:A Phase 1, open-label,randomized, crossover study. Adv Ther, 2020, 37(6):2696-2709.
• [24] Li Y, Ming JE, Kong F, et al. Bioequivalence study comparing f ixed-d ose com bi na t ion of clo pid og r el a nd as pi r i n wi t h coadministration of individual formulations in Chinese subjects under fed conditions:A Phase I, open-label, randomized, crossover study. Adv Ther, 2020, 37(11):4660-4674.
• [25] Lim S, Kim PJ, Baek C, et al. Antiplatelet e ffi cacy of fi xed-dose aspirin-clopidogrel combination in patients with stable coronary artery disease treated with drug-eluting stent implantation. Clin Drug Investig, 2015, 35(12):833-842.
• [26] Lim WH, Chae IH, Yoon CH, et al. Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen. A pooled analysis of individual patient data from the three MR-CAPCIS trials.Thromb Haemost, 2016, 116(1):78-86.
• [27] Koh JS, Park Y, Tantry US, et al. Pharmacodynamic eff ects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents:The ACCEL-COMBO trial. Platelets, 2017,28(2):187-193.
• [28] Chassot PG, Marcucci C, Delabays A, et al. Perioperative antiplatelet therapy. Am Fami Physician, 2010, 82(12):1484-1489.
• [29] Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors,and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement:results from the PREMIER registry. Circulation, 2006, 113(24):2803-2809.
• [30] Huber CA, Meyer MR, Steff el J, et al. Post-myocardial Infarction(MI)care:medication adherence for secondary prevention after MI in a large real-world population. Clin Ther, 2019, 41(1):107-117.
• [31] Deharo P, Quilici J, Bonnet G, et al. Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. Int J Cardiol, 2014, 172(1):e1-e2.
• [32] Maggioni AP, Dondi L, Pedrini A, et al. The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects. Eur Heart J Acute Cardiovasc Care, 2019, 8(6):527-535.
• [33] Roshandel G, Khoshnia M, Poustchi H, et al. Eff ectiveness of polypill for primary and secondary prevention of cardiovascular diseases(Poly Iran):a pragmatic, cluster-randomised trial. Lancet,2019, 394(10199):672-683.
• [34] Lin JK, Moran AE, Bibbins-Domingo K, et al. Cost-eff ectiveness of a f ixed-dose combination pill f or secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa:a modelling study. Lancet Glob Health, 2019, 7(10):e1346-e1358.
• [35] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg,2018, 53(1):34-78.
• [36] Kang J, Park KW, Palmerini T, et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy:individual patient level landmark Meta-analysis from Seven RCTs.Thromb Haemost, 2019, 119(1):149-162.
• [37]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志，2015,43(5):380-393.
• [38] Li C, Zhang L, Wang H, et al. Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention-A multicenter study.Int J Cardiol, 2017, 240:360-366.
• [39] Sun Y, Li C, Zhang L, et al. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients. Atherosclerosis, 2019,290:52-58.
• [40] Cuisset T,Deharo P,Quilici J,et al. Benefi t of switching dual antiplatelet therapy after acute coronary syndrome:the TOPIC(timing of platelet inhibition after acute coronary syndrome)randomized study. Eur Heart J,2017,38(41):3070-3078.
• [41] Park MW, Kim CJ, Kim MC, et al. A prospective, multicentre,randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention:rationale and design of the TALOS-AMI trial.Euro Intervention,2021,16(14):1170-1176.
• [42] HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy af ter percutaneous coronary inter vention(HOST-EXAM):a n investiga tor-initia ted,prospective, randomised, open-label, multicentre trial. Lancet,2021.[Online ahead of print]
• [43]中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员等.冠心病双联抗血小板治疗中国专家共识.中华心血管病杂志，2021, 49(5):432-454.
• [44] Hess CN, Becker RC, Alexander JH, et al. Antithrombotic therapy in heparin-induced thrombocytopenia:guidelines translated for the clinician. J Thromb Thrombolysis, 2012, 34(4):552-561.
• [45] Doesch C, Kr?mer B, Geisler T, et al. Challenges in the treatment of patients with essential thrombocythemia and acute coronary syndrome. J Thromb Thrombolysis, 2008, 25(2):193-197.
• [46]中国医师协会心血管内科医师分会，中国医师协会心血管内科医师分会血栓防治专业委员会，中华医学会消化内镜学分会，等.急性冠状动脉综合征抗栓治疗合并出血防治多学科专家共识.中华内科杂志，2016, 55(10):813-824.